131 related articles for article (PubMed ID: 9208145)
1. Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models.
Ballaz S; Barber A; Fortuño A; Del Río J; Martin-Martínez M; Gómez-Monterrey I; Herranz R; González-Muñiz R; García-López MT
Br J Pharmacol; 1997 Jun; 121(4):759-67. PubMed ID: 9208145
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis.
Latorre M; Bartolomé-Nebreda JM; García-López MT; González-Muñiz R; Herranz R; Del Río J; Cenarruzabeitia E
Pharmacology; 2004 Oct; 72(2):68-76. PubMed ID: 15331911
[TBL] [Abstract][Full Text] [Related]
3. The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle.
Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
Br J Pharmacol; 1995 Jan; 114(2):339-48. PubMed ID: 7881733
[TBL] [Abstract][Full Text] [Related]
4. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.
O'Neill MF; Dourish CT; Iversen SD
Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197
[TBL] [Abstract][Full Text] [Related]
5. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.
Gully D; Fréhel D; Marcy C; Spinazzé A; Lespy L; Neliat G; Maffrand JP; Le Fur G
Eur J Pharmacol; 1993 Feb; 232(1):13-9. PubMed ID: 7681406
[TBL] [Abstract][Full Text] [Related]
6. Several roles of CCKA and CCKB receptor subtypes in CCK-8-induced and LiCl-induced taste aversion conditioning.
Mosher JT; Johnson MF; Birkemo LS; Ervin GN
Peptides; 1996; 17(3):483-8. PubMed ID: 8735976
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.
Taniguchi H; Yazaki N; Endo T; Nagasaki M
Eur J Pharmacol; 1996 May; 304(1-3):147-54. PubMed ID: 8813597
[TBL] [Abstract][Full Text] [Related]
8. The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice.
Hendrie CA; Neill JC; Shepherd JK; Dourish CT
Physiol Behav; 1993 Oct; 54(4):689-93. PubMed ID: 7902586
[TBL] [Abstract][Full Text] [Related]
9. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
Boyle SJ; Tang KW; Woodruff GN; McKnight AT
Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
[TBL] [Abstract][Full Text] [Related]
10. Characterization of CCKA receptor mediated pepsinogen secretion in porcine chief cells.
Meyer G; Beinborn M; Sewing KF
Pharmacology; 1996 Jul; 53(1):48-59. PubMed ID: 8875601
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
Martín-Martínez M; Bartolomé-Nebreda JM; Gómez-Monterrey I; González-Muñiz R; García-López MT; Ballaz S; Barber A; Fortuño A; Del Río J; Herranz R
J Med Chem; 1997 Oct; 40(21):3402-7. PubMed ID: 9341915
[TBL] [Abstract][Full Text] [Related]
12. The effect of drugs acting on CCK receptors and rat free exploration in the exploration box.
Matto V; Harro J; Allikmets L
J Physiol Pharmacol; 1997 Jun; 48(2):239-51. PubMed ID: 9223028
[TBL] [Abstract][Full Text] [Related]
13. Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA, CCKB and mixed CCKA/B receptor antagonists.
Singh L; Field MJ; Hill DR; Horwell DC; McKnight AT; Roberts E; Tang KW; Woodruff GN
Eur J Pharmacol; 1995 Nov; 286(2):185-91. PubMed ID: 8605955
[TBL] [Abstract][Full Text] [Related]
14. CCKA and CCKB receptor subtypes both mediate the effects of CCK-8 on myenteric neurons in the guinea-pig ileum.
Schutte IW; Akkermans LM; Kroese AB
J Auton Nerv Syst; 1997 Dec; 67(1-2):51-9. PubMed ID: 9470144
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin-8S increases dynorphin B, aspartate and glutamate release in the fronto-parietal cortex of the rat via different receptor subtypes.
You ZB; Godukhin O; Goiny M; Nylander I; Ungerstedt U; Terenius L; Hökfelt T; Herrera-Marschitz M
Naunyn Schmiedebergs Arch Pharmacol; 1997 May; 355(5):576-81. PubMed ID: 9151295
[TBL] [Abstract][Full Text] [Related]
16. The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze.
Bickerdike MJ; Marsden CA; Dourish CT; Fletcher A
Eur J Pharmacol; 1994 Dec; 271(2-3):403-11. PubMed ID: 7705440
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini.
Tashiro M; Hirohata Y; Kihara Y; Akiyama T; Otsuki M
Pancreas; 1999 Mar; 18(2):156-64. PubMed ID: 10090413
[TBL] [Abstract][Full Text] [Related]
18. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.
Singh L; Field MJ; Hughes J; Menzies R; Oles RJ; Vass CA; Woodruff GN
Br J Pharmacol; 1991 Sep; 104(1):239-45. PubMed ID: 1686205
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological study of gastrin-mediated amylase release in pancreatic acinar cells (AR4-2J).
Bertrand V; Bastié MJ; Bigaud C; Pyronnet S; Vaysse N; Pradayrol L
Regul Pept; 1994 Dec; 54(2-3):513-25. PubMed ID: 7536336
[TBL] [Abstract][Full Text] [Related]
20. Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.
Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
Br J Pharmacol; 1992 May; 106(1):61-6. PubMed ID: 1504732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
